The incubator is home to more than 50 biotech startups. In the first half of last year alone, €140 million flowed into IZB companies. €95 million of this went to Origenis and its US joint venture with Kleiner Perkins. In the second half of 2021, a further €23 million in financing for IZB companies followed. The biotechnology company Eisbach Bio received a Funding of over 8 million euros from the Federal Ministry of Education and Research for the clinical development of a COVID-19 drug. In October, a further funding from the Bavarian State Ministry of Economic Affairs, Regional Development and Energy in the amount of €6.7 million. In November, Scirhom, a developer of novel antibody therapies, increased its seed financing from High-Tech Gründerfonds and other private investors by €8 million, bringing the total to €16 million.
This year, a major financing round has already been successfully completed in incubator completed: The American company Bruker has invested 13.5 million euros in the laboratory startup Preomics boarded.
The IZB as 'Munich's Silicon Valley'
Peter Hanns Zobel, Managing Director of the IZB for 25 years, says:
"We are particularly proud that last year was largely a follow-on financing exercise, demonstrating the sustained interest of investors in the startups at the IZB. This growth, along with the promising scientific advances of the companies, once again underscores the IZB's reputation as 'Munich's Silicon Valley,' which, as a leading technology center, offers excellent conditions for the development of new drugs and therapies."
